Since last August, the world's biggest generics drugmaker has seen its share price fall over 40 percent due to a decline in U.S. generic drug prices and copycat competition for its blockbuster multiple sclerosis drug Copaxone. (cnbc.com)
Teva beats first - quarter expectations but still has the same old problems Copaxone's market share and new generic launches helped Teva to forecast - beating profit and revenue but problems persistTeva had to make pricing concessions on its flagship multiple sclerosis drug Copaxone, and now expects a delay in approval of a key migraine drug, fremanezumab. (marketwatch.com)
Biogen, AbbVie — The drugmakers have withdrawn their multiple sclerosis drug Zinbryta worldwide due to safety issues. (cnbc.com)